Effects of vasopeptidase inhibition on renal function and tubuloglomerular feedback in spontaneously hypertensive rats

Hypertension Research

Volumn 28, Issue 7, 2005, Pages 611-618

  Wang, Tao ^a   Takabatake, Toshikazu ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Macula densa; Omapatrilat; Spontaneously hypertensive rat; Tubuloglomerular feedback; Vasopeptidase inhibitor

Indexed keywords

7 NITROINDAZOLE; DRUG VEHICLE; NITRIC OXIDE; OMAPATRILAT; SODIUM; VASOPEPTIDASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; FEEDBACK SYSTEM; FLOW RATE; GLOMERULUS FILTRATION RATE; HENLE LOOP; JUXTAGLOMERULAR APPARATUS; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY PERFUSION; KIDNEY VASCULAR RESISTANCE; MALE; NONHUMAN; PUNCH BIOPSY; RAT; RENOVASCULAR HYPERTENSION; SIGNAL TRANSDUCTION; SODIUM URINE LEVEL; SPONTANEOUSLY HYPERTENSIVE RAT; VASODILATATION;

ANIMALS; FEEDBACK, BIOCHEMICAL; GLOMERULAR FILTRATION RATE; HYPERTENSION; KIDNEY GLOMERULUS; KIDNEY TUBULES; LOOP OF HENLE; MALE; NITRIC OXIDE; PROTEASE INHIBITORS; PYRIDINES; RATS; RATS, INBRED SHR; THIAZEPINES;

EID: 25844520797     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.28.611     Document Type: Article

References (41)

1. Weber M: Emerging treatments for hypertension: potential role for vasopeptidase inhibition. Am J Hypertens 1999; 12: S139-S147.
2. Corti R, Burnett JC, Rouleau JL, Ruschitzka F, Luscher TF: Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation 2001; 104: 1856-1862.
3. Trippodo NC, Robl JA, Asaad MM, Fox M, Panchal BC, Schaeffer TR: Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens 1998; 11: 363-372.
4. Groholm T, Finckenberg P, Palojoki E, et al: Cardioprotective effects of vasopeptidase inhibition vs. angiotensin type 1-receptor blockade in spontaneously hypertensive rats on a high salt diet. Hypertens Res 2004; 27: 609-618.
5. Campese VM, Lasseter KC, Ferrario CM, et al: Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients. Hypertension 2001; 38: 1342-1348.
6. McClean DR, Ikram H, Garlick AH, Richards AM, Nicholls MG, Crozier IG: The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol 2000; 36: 479-486.
7. Schnermann J: Juxtaglomerular cell complex in the regulation of renal salt excretion. Am J Physiol 1998; 274: R263-R279.
8. Dilley JR, Stier CT Jr, Arendshorst WJ: Abnormalities in glomerular function in rats developing spontaneous hypertension. Am J Physiol 1984; 246: F12-F20.
9. Takabatake T, Ushiogi Y, Ohta K, Hattori N: Attenuation of enhanced tubuloglomerular feedback activity in SHR by renal denervation. Am J Physiol 1990; 258: F980-F985.
10. 1 receptors. Am J Physiol 1996; 270: F749-F755.
11. Kovacs G, Komlosi P, Fuson A, Peti-Peterdi J, Rosivall L, Bell PD: Neuronal nitric oxide synthase: its role and regulation in macula densa cells. J Am Soc Nephrol 2003; 14: 2475-2483.
12. Thorup C, Persson AE: Impaired effect of nitric oxide synthesis inhibition on tubuloglomerular feedback in hypertensive rats. Am J Physiol 1996; 271: F246-F252.
13. Persson AE, Gutierrez A, Pittner J, et al: Renal NO production and the development of hypertension. Acta Physiol Scand 2000; 168: 169-174.
14. Haberle DA, Davis JM, Kawabata M, Metz C, Wapler P, Stachl M: Renal and single-nephron function is comparable in thiobutabarbitone- and thiopentone-anaesthetised rats. Pflügers Arch 1993; 424: 224-230.
15. Seymour AA, Mathers P: BMS 186, 716 in conscious sodium replete monkeys: effects on blood pressure, heart rate and renal function. Bristol-Myers Squibb Pharmacol Rep 1993; September 13.
16. Seymour AA, Asaad M, Mathers P: BMS 186, 716 in conscious sodium replete monkeys: urinary ANP and cyclic GMP excretion. Bristol-Myers Squibb Pharmacol Rep 1994; September 9.
17. Wolff DJ, Gribin BJ: The inhibition of the constitutive and inducible nitric oxide synthase isoforms by indazole agents. Arch Biochem Biophys 1994; 311: 300-306.
18. Welch WJ, Tojo A, Lee JU, Kang DG, Schnackenberg CG, Wilcox CS: Nitric oxide synthase in the JGA of the SHR: expression and role in tubuloglomerular feedback. Am J Physiol 1999; 277: F130-F138.
19. Ise T, Takabatake T, Ohta H, et al: Effects of atrial natriuretic polypeptide on renal microcirculation. Microcirculation Annu 1989; 5: 137-138.
20. Kawabata M: Effects of atrial natriuretic polypeptide on tubuloglomerular feedback. J Juzen Med Soc 1989; 98: 477-488 (in Japanese).
21. Taal MW, Nenov VD, Wong WC, et al: Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. J Am Soc Nephrol 2001; 12: 2051-2059.
22. Zhou X, Ono H, Ono Y, Frohlich ED: Renoprotective effects of omapatrilat are mediated partially by bradykinin. Am J Nephrol 2003; 23: 214-221.
23. Schmitt F, Martinez F, Ikeni A, et al: Acute renal effects of neutral endopeptidase inhibition in humans. Am J Physiol 1994; 267: F20-F27.
24. Cao Z, Burrell LM, Tikkanen I, Bonnet F, Cooper ME, Gilbert RE: Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney Int 2001; 60: 715-721.
25. Benigni A, Zoja C, Zatelli C, et al: Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy. Kidney Int 2004; 66: 1959-1965.
26. Massien C, Azizi M, Guyene TT, Vesterqvist O, Mangold B, Menard J: Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans. Clin Pharmacol Ther 1999; 65: 448-459.
27. Rousso P, Buclin T, Nussberger J, et al: Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100,240, on endocrine and renal functions in healthy volunteers. J Hypertens 1999; 17: 427-437.
28. Seymour AA, Asaad MM, Abboa-Offei BE, Smith PL, Rogers WL, Dorso CR: Determinants of in vivo activity of neutral endopeptidase 3.4.24.11 and angiotensin converting enzyme inhibitors. J Pharmacol Exp Ther 1996; 276: 708-713.
29. Zeidel ML: Renal actions of atrial natriuretic peptide: regulation of collecting duct sodium and water transport. Annu Rev Physiol 1990; 52: 747-759.
30. Davis CL, Briggs JP: Effect of reduction in renal artery pressure on atrial natriuretic peptide-induced natriuresis. Am J Physiol 1987; 252: F146-F153.
31. Seymour AA, Fennell SA, Swerdel JN: Potentiation of renal effects of atrial natriuretic factor-(99-126) by SQ 29,072. Hypertension 1989; 14: 87-97.
32. Motwani JG, Lang CC, Cramb G, Struthers AD: Natriuretic response to neutral endopeptidase inhibition is blunted by enalapril in healthy men. Hypertension 1995; 25: 637-642.
33. Inoue T, Nonoguchi H, Tomita K: Physiological effects of vasopressin and atrial natriuretic peptide in the collecting duct. Cardiovasc Res 2001; 51: 470-480.
34. Schiltz JC, Hoffman GE, Stricker EM, Sved AF: Decreases in arterial pressure activate oxytocin neurons in conscious rats. Am J Physiol 1997; 273: R1474-R1483.
35. Gebremedhin D, Fenoy FJ, Harder DR, Roman RJ: Enhanced vascular tone in the renal vasculature of spontaneously hypertensive rats. Hypertension 1990; 16: 648-654.
36. Takabatake T, Ushiogi Y, Ise T, Kobayashi K: Effect of calcium antagonist, manidipine hydrochloride, on renal hemodynamics and tubuloglomerular feedback in spontaneously hypertensive rats. Am Heart J 1993; 125: 578-581.
37. Thomson SC, Bachmann S, Bostarjoglo M, et al: Temporal adjustment of the juxtaglomerular apparatus during sustained inhibition of proximal reabsorption. J Clin Invest 1999; 104: 1149-1158.
38. Ollerstam A, Pittner J, Persson AE, Thorup C: Increased blood pressure in rats after long-term inhibition of the neuronal isoform of nitric oxide synthase. J Clin Invest 1997; 99: 2212-2218.
39. Liao WC, Vesterqvist O, Delaney C, et al: Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects. Br J Clin Pharmacol 2003; 56: 395-406.
40. Schuermann J, Briggs JP: Interaction between loop of Henle flow and arterial pressure as determinants of glomerular pressure. Am J Physiol 1989; 256: F421-F429.
41. Moore LC: Tubuloglomerular feedback and SNGFR autoregulation in the rat. Am J Physiol 1984; 247: F267-F276.